Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Cancer Treatment Reviews|September 8, 2009
Clinical pharmacokinetics of tyrosine kinase inhibitorsNielka P van Erp, Hans Gelderblom, Henk-Jan Guchelaar
Cancer Chemotherapy and Pharmacology|December 2, 2021
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascitesStefanie D Krens, Sasja F Mulder, Nielka P van Erp
Nederlands Tijdschrift Voor Geneeskunde|December 4, 2014
[Determination of blood levels for oral anticancer drugs]Nielka P van Erp, Winette T A van der Graaf
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2021
Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to ProofLoek A W de Jong, Nielka P van Erp, Lana Bijelic
British Journal of Clinical Pharmacology|May 22, 2019
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness studySander Zuidema, Ingrid M E Desar, Nielka P van Erp, et al.
Cancer Chemotherapy and Pharmacology|April 5, 2021
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy-naïve patient: a case reportEmmy Boerrigter, Thomas Havenith, Nielka P van Erp, et al.
Drug Discovery Today|September 24, 2014
Individualized dosing of tyrosine kinase inhibitors: are we there yet?Djoeke de Wit, Henk-Jan Guchelaar, Jan den Hartigh, et al.
Expert Review of Molecular Diagnostics|October 3, 2019
Clinical utility of emerging biomarkers in prostate cancer liquid biopsiesEmmy Boerrigter, Levi N Groen, Nielka P Van Erp, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 19, 2019
Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MSMinou van Seyen, Marga J A de Graaff Teulen, Nielka P van Erp, et al.
Cancer Chemotherapy and Pharmacology|February 21, 2020
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patientsGuillemette E Benoist, Inge M van Oort, David M Burger, et al.
Pageof 11